Equities research analysts at FBN Securities upgraded shares of Research In Motion (NASDAQ: RIMM) from a “sell” rating to an “outperform” rating in a research note to clients and investors on Tuesday.
Separately, analysts at BNP Paribas (EPA: BNP) downgraded shares of Research In Motion from an “outperform” rating to a “neutral” rating in a research note to investors on Monday.
Research In Motion Limited (RIM) is a designer, manufacturer and marketer of wireless solutions for the worldwide mobile communications market. Through the development of integrated hardware, software and services that support multiple wireless network standards, RIM provides platforms and solutions for seamless access to time-sensitive information, including e-mail, phone, short message service (SMS), Internet and intranet-based applications. RIM’s portfolio of products, services and embedded technologies are used by organizations worldwide and include the BlackBerry wireless solution, the RIM Wireless Handheld product line, software development tools and other software and hardware. Its subsidiaries include Research In Motion Corporation, Research In Motion UK Limited and RIM Finance, LLC. On June 2, 2010, Harman International sold its software operating systems unit, QNX Software Systems, to the Company.
Shares of Research In Motion (NASDAQ: RIMM) traded down 2.38% during mid-day trading on Wednesday, hitting $59.01. Research In Motion has a 52 week low of $42.53 and a 52 week high of $76.95. The stock’s 50-day moving average is $58.48 and its 200-day moving average is $53.50. On average, analysts predict that Research In Motion will post $1.61 EPS next quarter. The company has a market cap of $30.846 billion and a price-to-earnings ratio of 11.64.
IP/10/252
Brussels, 9 th March 2010
European Commission unveils new research projects to fight influenza
Today, the European Commission has announced the results of its €18 million call for proposals for new research projects on influenza. Four collaborative research projects have been shortlisted for funding. They involve 52 research institutes and SMEs from 18 European countries and 3 international partners (Israel, China, the United States). Influenza virus genes migrate across continents and between species and seriously threaten both human and animal health. Two consortia will focus their research on influenza in pigs while the two others will develop innovative drugs against influenza in humans. Their selection is part of the EU's longstanding support for research on influenza and brings the total Commission funding in this field to over €100 million since 2001.
EU Commissioner for Research, Innovation and Science Máire Geoghegan-Quinn said: "Seasonal flu alone can kill 250,000 – 500,000 people worldwide every year and EU-funded research projects like these can help save lives. What is more, successful EU research in preventing and treating flu and other diseases has enormous social and economic value and can contribute significantly to our Europe 2020 goals".
Next steps
Final EU contribution per project and project details will be subject to the signature of contracts which should take place in 2010.
Background
The €18 million call for proposals for new research projects on influenza was launched in July 2009. 17 proposals were submitted.
Details of new influenza research projects announced today – more information and scientific background on the projects below at:
http://ec.europa.eu/research/index.cfm?pg=newsalert&lg=en&year=2010&na=na-090310-annexes
ESNIP 3 - European surveillance network for influenza in pigs 3
This ESNIP 3 project will maintain and expand the surveillance network for influenza in pigs established during the previous EU funded projects ESNIP 1 and ESNIP 2 which represented the only organised surveillance network of this kind. The project is expected to contribute to improved pandemic preparedness and planning for human influenza and provide an evidence base for decisions in relation to veterinary health.
Duration: 36 months
Expected EU contribution: €1 million
Coordinator: Ian Brown, The Veterinarian Laboratories Agency (United Kingdom), i.h.brown@vla.defra.gsi.gov.uk .
Contact for the press: Jane Goodger, j.goodger@vla.defra.gsi.gov.uk
25 Partners from 15 countries: United Kingdom, Belgium, France, Italy, Denmark, Poland, Spain, Germany, Finland, Hungary, The Netherlands, Greece, Israel, China and the United States.
FLUPIG - Pathogenesis and transmission of influenza virus in pigs
This project aims at a better understanding of the role of pigs in influenza pandemics. The exact role of pigs is unclear, as is the nature of the genetic changes that are required for (a) efficient replication of an avian virus in pigs, (b) efficient transmission of avian viruses between pigs and (c) virus transmission from pigs to humans and between humans. More knowledge of this will be critical to the control of future influenza pandemics
Duration: 48 months
Expected EU contribution: €5 million
Coordinator: Kristien van Reeth, Faculty of Veterinary Medicine, Ghent University, (Belgium), kristien.vanreeth@ugent.be
10 Partners from 8 countries: Belgium, Italy, United Kingdom, Germany, The Netherlands, Poland, China (Hong-Kong) and the United States.
FLU-PHARM - New drugs targeting influenza virus
The project FLU-PHARM will develop new drug candidates that inhibit viral replication in infected cells (by targeting the PB2 and PA protein domains). Such drugs are expected to have a reduced risk of patients developing resistance to them and less undesirable side-effects. If successful, FLU-PHARM will provide new opportunities for treating both seasonal and pandemic flu.
Duration: 42 months
Expected EU contribution: €6 million
Coordinator: Stephen Cusack, European Molecular Biology Laboratory (France) cusack@embl.fr
14 Partners from 7 countries: Germany, Austria, France, Spain, Slovakia, Belgium, Sweden
FLUCURE - Development of novel antiviral drugs against Influenza
The FLUCURE project will also targets the viral replication machinery (with a different approach as it will target the PB1/PA proteins and NP proteins) and aims to develop new drug candidates with reduced risk of resistance. The objective is to deliver one or more drug candidates suitable for entering clinical development within four years.
Duration: 48 months
Expected EU contribution: €6 million
Coordinator: Heather Marshall-Heyman, VIRONOVA AB (Sweden), heather.marshall-heyman@vironova.com
9 Partners from 7 European countries: Sweden, Switzerland, Bulgaria, The Netherlands, Lithuania, Germany, Italy
Reference research: finance research and computer research and sport research and recent update
Best Hosting
